June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC
G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement in overall survival in metastatic triple negative breast cancer patients receiving trilaciclib and chemotherapy. The company will present detailed data from the trial of the selective CDK4 and CDK6 inhibitor at a medical meeting this year.

Linzess meets in Phase IIIb for IBS-C
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) reported that Linzess linaclotide met the primary and secondary endpoints in a Phase IIIb trial to address bloating and other symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C), setting the companies up to potentially change how doctors and patients think about treatment goals (see “Getting to the Point in IBS”)...